VivoSim Labs (NASDAQ:VIVS – Get Free Report) and MaxCyte (NASDAQ:MXCT – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for VivoSim Labs and MaxCyte, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VivoSim Labs | 1 | 0 | 0 | 0 | 1.00 |
| MaxCyte | 1 | 1 | 1 | 0 | 2.00 |
MaxCyte has a consensus price target of $5.00, suggesting a potential upside of 354.55%. Given MaxCyte’s stronger consensus rating and higher possible upside, analysts plainly believe MaxCyte is more favorable than VivoSim Labs.
Insider & Institutional Ownership
8.2% of VivoSim Labs shares are owned by institutional investors. Comparatively, 68.8% of MaxCyte shares are owned by institutional investors. 1.0% of VivoSim Labs shares are owned by company insiders. Comparatively, 4.1% of MaxCyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
VivoSim Labs has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.
Profitability
This table compares VivoSim Labs and MaxCyte’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VivoSim Labs | -11,016.07% | -612.23% | -177.02% |
| MaxCyte | -81.40% | -14.71% | -12.60% |
Valuation and Earnings
This table compares VivoSim Labs and MaxCyte”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VivoSim Labs | $130,000.00 | 19.73 | -$13.84 million | ($4.47) | -0.03 |
| MaxCyte | $33.03 million | 3.44 | -$44.63 million | ($0.33) | -3.33 |
VivoSim Labs has higher earnings, but lower revenue than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.
Summary
MaxCyte beats VivoSim Labs on 10 of the 13 factors compared between the two stocks.
About VivoSim Labs
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds.
About MaxCyte
MaxCyte, Inc. (NASDAQ: MXCT) is a life sciences company that develops technologies for engineering cells used in biopharmaceutical research and the development of cell-based therapies. Its platform is designed to help researchers modify cells efficiently for applications including cell therapy, gene editing, immuno-oncology and other advanced biological treatments. The company’s primary offering is the ExPERT platform, which combines Flow Electroporation technology with specialized instruments, single-use processing assemblies, software and related support services.
Receive News & Ratings for VivoSim Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VivoSim Labs and related companies with MarketBeat.com's FREE daily email newsletter.
